To determine how polymorphisms in the stress hormone receptor ADRB2 affect treatments in patients with Triple Negative Breast Cancer

Medicine & Life Sciences

1. Adrenergic beta-2 Receptors 100%
2. Triple Negative Breast Neoplasms 95%
3. Hormones 72%
4. Breast Neoplasms 55%
5. Haplotypes 44%
6. Codon 23%
7. Recurrence 22%
8. Drug Therapy 18%
9. Neoplasms 17%
10. Genetic Variation 15%
11. Epinephrine 14%
12. Therapeutics 14%
13. Norepinephrine 13%
14. Single Nucleotide Polymorphism 13%
15. Tissue Banks 11%
16. Immunohistochemistry 10%
17. Gene Editing 9%
18. Receptors, Adrenergic, beta 9%
19. Linkage Disequilibrium 9%
20. Cell Surface Receptors 8%
21. Formaldehyde 7%
22. Paraffin 7%
23. Alleles 5%